These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 17568025)

  • 61. Erythropoiesis-stimulating agents in the treatment of cancer-associated anemia.
    Kara O; Dizdar O; Altundag K
    JAMA; 2008 Dec; 300(24):2855; author reply 2855-7. PubMed ID: 19109113
    [No Abstract]   [Full Text] [Related]  

  • 62. Health economic evaluation of treating anemia in cancer patients receiving chemotherapy: a study in Belgian hospitals.
    Spaepen E; Demarteau N; Van Belle S; Annemans L
    Oncologist; 2008 May; 13(5):596-607. PubMed ID: 18515745
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Strategies to optimize the use of erythropoietin and iron therapy in oncology patients.
    Ford PA; Mastoris J
    Transfusion; 2004 Dec; 44(12 Suppl):15S-25S. PubMed ID: 15585001
    [No Abstract]   [Full Text] [Related]  

  • 64. Darbepoetin alfa and chronic kidney disease.
    Hampl H; Kovesdy CP; Kalantar-Zadeh K
    N Engl J Med; 2010 Feb; 362(7):654; author reply 655. PubMed ID: 20187260
    [No Abstract]   [Full Text] [Related]  

  • 65. Lack of data mires Aranesp in controversy.
    Wadman M
    Nat Biotechnol; 2007 Nov; 25(11):1193. PubMed ID: 17989655
    [No Abstract]   [Full Text] [Related]  

  • 66. The FDA black box for EPO: what should nephrologists do?
    Singh AK
    Nephrol News Issues; 2007 May; 21(6):55-6, 58-9. PubMed ID: 17518125
    [No Abstract]   [Full Text] [Related]  

  • 67. The TREAT study answers a question, not the question.
    Coyne DW
    Am J Kidney Dis; 2008 Sep; 52(3):626-7; author reply 627-8. PubMed ID: 18725019
    [No Abstract]   [Full Text] [Related]  

  • 68. Time to Reconsider Evidence for Anaemia Treatment (TREAT) = Essential Safety Arguments (ESA).
    Goldsmith D; Covic A
    Nephrol Dial Transplant; 2010 Jun; 25(6):1734-7. PubMed ID: 20200007
    [No Abstract]   [Full Text] [Related]  

  • 69. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in anemic predialysis chronic kidney disease patients from an observational study.
    Papatheofanis F; Smith C; Mody S; McKenzie RS; Bookhart B; Piech CT
    Am J Ther; 2007; 14(4):322-7. PubMed ID: 17667204
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy.
    Wauters I; Vansteenkiste J
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1383-90. PubMed ID: 23113603
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Budget impact analysis of darbepoetin alfa every 3 weeks versus epoetin alfa every week for the treatment of chemotherapy-induced anaemia from a US payer's perspective.
    Rubin RJ; Glaspy JA; Adams JL; Mafilios MS; Wang SM; Viswanathan HN; Kallich JD
    J Med Econ; 2008; 11(2):199-213. PubMed ID: 19450080
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease.
    Vaziri ND; Zhou XJ
    Nephrol Dial Transplant; 2009 Apr; 24(4):1082-8. PubMed ID: 18987263
    [No Abstract]   [Full Text] [Related]  

  • 73. FDA likely to further restrict erythropoietin use for cancer patients.
    Fox JL
    Nat Biotechnol; 2007 Jun; 25(6):607-8. PubMed ID: 17557084
    [No Abstract]   [Full Text] [Related]  

  • 74. Drug utilisation and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care database.
    Vekeman F; McKenzie RS; Bookhart BK; Laliberté F; Duh MS; Tak Piech C; Lefebvre P
    J Med Econ; 2009 Mar; 12(1):1-8. PubMed ID: 19450059
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Epoietins (EPO)].
    Taeron C
    Rev Infirm; 2007 Oct; (134):55-6. PubMed ID: 18087795
    [No Abstract]   [Full Text] [Related]  

  • 76. Questionable conclusions about epoetin alfa.
    Kruse MW; Lee JJ
    Am J Health Syst Pharm; 2007 Sep; 64(17):1789-90; author reply 1790-1. PubMed ID: 17724355
    [No Abstract]   [Full Text] [Related]  

  • 77. Reevaluating erythropoiesis-stimulating agents.
    Cotter DJ
    N Engl J Med; 2010 May; 362(18):1743; author reply 1743-4. PubMed ID: 20449881
    [No Abstract]   [Full Text] [Related]  

  • 78. The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia.
    Ben-Hamadi R; Duh MS; Aggarwal J; Henckler A; McKenzie RS; Tak Piech C
    Curr Med Res Opin; 2005 Oct; 21(10):1677-82. PubMed ID: 16238908
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Treatment of anemia in myelodysplastic syndrome with darbepoetin and granulocyte colony stimulating factor.
    Rose S; Ali Y; Maffei B; Saidi P
    Am J Hematol; 2007 Mar; 82(3):245-6. PubMed ID: 16924646
    [No Abstract]   [Full Text] [Related]  

  • 80. The impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa.
    Song X; Long SR; Marder WD; Sullivan SD; Kallich J
    Ann Pharmacother; 2009 Jul; 43(7):1203-10. PubMed ID: 19584392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.